Zhao Y, Dai X, Blackwell HE, Schreiber SL, Chory J. SIR1, an upstream component in auxin signaling identified by chemical genetics. Science. 2003;301(5636):1107-10. doi:10.1126/science.1084161
Abudayyeh OO, Gootenberg JS, Essletzbichler P, et al. RNA targeting with CRISPR-Cas13. Nature. 2017;550(7675):280-284. doi:10.1038/nature24049
Hazelbaker DZ, Beccard A, Bara AM, et al. A Scaled Framework for CRISPR Editing of Human Pluripotent Stem Cells to Study Psychiatric Disease. Stem Cell Reports. 2017;9(4):1315-1327. doi:10.1016/j.stemcr.2017.09.006
Ho SN, Biggar SR, Spencer DM, Schreiber SL, Crabtree GR. Dimeric ligands define a role for transcriptional activation domains in reinitiation. Nature. 1996;382(6594):822-6. doi:10.1038/382822a0
Graef IA, Holsinger LJ, Diver S, Schreiber SL, Crabtree GR. Proximity and orientation underlie signaling by the non-receptor tyrosine kinase ZAP70. EMBO J. 1997;16(18):5618-28. doi:10.1093/emboj/16.18.5618
Belshaw PJ, Ho SN, Crabtree GR, Schreiber SL. Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. Proc Natl Acad Sci U S A. 1996;93(10):4604-7.
Fass DM, Reis SA, Ghosh B, et al. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity. Neuropharmacology. 2013;64:81-96. doi:10.1016/j.neuropharm.2012.06.043
Belshaw PJ, Spencer DM, Crabtree GR, Schreiber SL. Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization. Chem Biol. 1996;3(9):731-8.
Lucas D, O’Leary HA, Ebert BL, Cowan CA, Tremblay CS. Utility of CRISPR/Cas9 systems in hematology research. Exp Hematol. 2017;54:1-3. doi:10.1016/j.exphem.2017.06.006
Floto A, Sarkar S, Perlstein EO, Kampmann B, Schreiber SL, Rubinsztein DC. Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington’s disease models and enhance killing of mycobacteria by macrophages. Autophagy. 2007;3(6):620-2.